Integra Therapeutics at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Integra Therapeutics brings 4 presentations to ESGCT 2026 in Hamburg. Its work centres on a gene writing platform that inserts kilobase-sized payloads at chosen sites in the genome. Applications shown include liver-directed treatment given in the body, a version that avoids viral delivery, and precise integration for CAR T production.
| Organization | ESGCT 2026 Attendance |
|---|---|
Integra Therapeutics Barcelona, Spain | |
Develops FiCAT, a gene writing platform combining CRISPR-Cas targeting with an engineered piggyBac transposase to insert large payloads, for CAR-T and in vivo therapies. | Poster Wed Oct 28 1:30pm–3:30pm FiCAT gene writing platform for liver-directed in vivo gene therapy Poster Wed Oct 28 1:30pm–3:30pm Programmable genomic insertion of kilobase sized payloads via FiCAT 2.0 gene writing platform Poster Thu Oct 29 2:00pm–4:00pm Development of viral-free FiCAT gene writing platform for liver-directed in vivo application Poster Thu Oct 29 2:00pm–4:00pm FiCAT: Precise Genomic Integration for Advanced CAR-T Production |
Instantly find 20 buyers from Integra Therapeutics
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction